Baird Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $33M | Sell |
52,845
-4,744
| -8% | -$3.23M | 0.05% | 266 |
|
|
2026
Q1 | $44.5M | Buy |
57,589
+7,719
| +15% | +$5.91M | 0.07% | 188 |
|
|
2025
Q4 | $38.5M | Buy |
49,870
+1,484
| +3% | +$1.01M | 0.06% | 213 |
|
|
2025
Q3 | $27.2M | Sell |
48,386
-593
| -1% | -$335K | 0.04% | 309 |
|
|
2025
Q2 | $25.7M | Buy |
48,979
+4,383
| +10% | +$2.45M | 0.05% | 310 |
|
|
2025
Q1 | $28.3M | Buy |
44,596
+9,883
| +28% | +$6.8M | 0.05% | 273 |
|
|
2024
Q4 | $24.7M | Sell |
34,713
-1,135
| -3% | -$953K | 0.05% | 299 |
|
|
2024
Q3 | $37.7M | Buy |
35,848
+1,155
| +3% | +$1.29M | 0.07% | 238 |
|
|
2024
Q2 | $36.5M | Buy |
34,693
+761
| +2% | +$738K | 0.08% | 238 |
|
|
2024
Q1 | $32.7M | Buy |
33,932
+71
| +0.2% | +$67.5K | 0.07% | 249 |
|
|
2023
Q4 | $29.7M | Buy |
33,861
+255
| +0.8% | +$210K | 0.07% | 252 |
|
|
2023
Q3 | $27.7M | Buy |
33,606
+295
| +0.9% | +$232K | 0.08% | 233 |
|
|
2023
Q2 | $23.9M | Buy |
33,311
+1,885
| +6% | +$1.45M | 0.06% | 264 |
|
|
2023
Q1 | $25.8M | Sell |
31,426
-4,064
| -11% | -$3.07M | 0.06% | 266 |
|
|
2022
Q4 | $25.6M | Sell |
35,490
-24
| -0.1% | -$17.7K | 0.07% | 264 |
|
|
2022
Q3 | $24.5M | Sell |
35,514
-1,481
| -4% | -$932K | 0.07% | 255 |
|
|
2022
Q2 | $21.9M | Buy |
36,995
+466
| +1% | +$303K | 0.06% | 289 |
|
|
2022
Q1 | $25.5M | Buy |
36,529
+18,345
| +101% | +$11.6M | 0.06% | 273 |
|
|
2021
Q4 | $11.5M | Sell |
18,184
-1,116
| -6% | -$686K | 0.03% | 408 |
|
|
2021
Q3 | $11.7M | Buy |
19,300
+4,073
| +27% | +$2.53M | 0.03% | 391 |
|
|
2021
Q2 | $8.51M | Buy |
15,227
+2,458
| +19% | +$1.25M | 0.02% | 459 |
|
|
2021
Q1 | $6.04M | Buy |
12,769
+4,293
| +51% | +$2.09M | 0.02% | 524 |
|
|
2020
Q4 | $4.09M | Buy |
8,476
+439
| +5% | +$237K | 0.01% | 601 |
|
|
2020
Q3 | $4.5M | Buy |
8,037
+310
| +4% | +$188K | 0.02% | 513 |
|
|
2020
Q2 | $2.13M | Sell |
7,727
-339
| -4% | -$192K | 0.01% | 709 |
|
|
2020
Q1 | $3.94M | Sell |
8,066
-2,033
| -20% | -$839K | 0.02% | 498 |
|
|
2019
Q4 | $3.79M | Sell |
10,099
-3,169
| -24% | -$1.07M | 0.01% | 597 |
|
|
2019
Q3 | $1.34M | Sell |
13,268
-8,199
| -38% | -$2.43M | 0.01% | 900 |
|
|
2019
Q2 | $6.72M | Buy |
21,467
+4,766
| +29% | +$1.59M | 0.03% | 440 |
|
|
2019
Q1 | $6.86M | Sell |
16,701
-412
| -2% | -$170K | 0.04% | 377 |
|
|
2018
Q4 | $6.39M | Sell |
17,113
-317
| -2% | -$116K | 0.04% | 375 |
|
|
2018
Q3 | $6.94M | Sell |
17,430
-396
| -2% | -$151K | 0.04% | 381 |
|
|
2018
Q2 | $6.15M | Buy |
17,826
+779
| +5% | +$244K | 0.04% | 386 |
|
|
2018
Q1 | $5.87M | Buy |
17,047
+1,297
| +8% | +$451K | 0.04% | 393 |
|
|
2017
Q4 | $5.92M | Buy |
15,750
+2,122
| +16% | +$859K | 0.04% | 390 |
|
|
2017
Q3 | $6.09M | Sell |
13,628
-4,018
| -23% | -$1.91M | 0.05% | 379 |
|
|
2017
Q2 | $8.67M | Buy |
17,646
+610
| +4% | +$267K | 0.07% | 284 |
|
|
2017
Q1 | $6.6M | Sell |
17,036
-108
| -0.6% | -$40K | 0.05% | 341 |
|
|
2016
Q4 | $6.29M | Buy |
17,144
+221
| +1% | +$84K | 0.05% | 324 |
|
|
2016
Q3 | $6.8M | Sell |
16,923
-4,473
| -21% | -$1.79M | 0.06% | 314 |
|
|
2016
Q2 | $7.48M | Buy |
21,396
+686
| +3% | +$264K | 0.07% | 289 |
|
|
2016
Q1 | $7.46M | Buy |
20,710
+4,116
| +25% | +$1.7M | 0.07% | 272 |
|
|
2015
Q4 | $9.01M | Buy |
16,594
+1,834
| +12% | +$994K | 0.09% | 235 |
|
|
2015
Q3 | $6.87M | Sell |
14,760
-8
| -0.1% | -$4.3K | 0.07% | 270 |
|
|
2015
Q2 | $7.53M | Buy |
+14,768
| New | +$7.21M | 0.07% | 257 |
|
Other funds holding REGN
Baird Financial Group's REGN Position: Q2 2026 in Review
Baird Financial Group reduced its Regeneron Pharmaceuticals (REGN) stake by 8.2% in Q2 2026, selling an estimated $3.23M and leaving 52,845 shares worth $33M. The position accounts for 0.05% of the portfolio, ranked #266.
Baird Financial Group first reported a position in REGN in Q2 2015 and has held it in 45 quarters since. The position peaked at $44.5M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Baird Financial Group held 52,845 shares of Regeneron Pharmaceuticals worth $33M as of Q2 2026.
- Baird Financial Group sold 4,744 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.23M.
- Regeneron Pharmaceuticals made up 0.05% of Baird Financial Group's portfolio in Q2 2026, its #266 holding.
- Baird Financial Group first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
- Baird Financial Group's Regeneron Pharmaceuticals position peaked at $44.5M in Q1 2026.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.